Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia

European Journal of Neuroscience

Volumn 38, Issue 1, 2013, Pages 2192-2198

  Mahmoudi, Souha ^a   Blanchet, Pierre J ^a   Lévesque, Daniel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

abnormal involuntary movements; antipsychotic drug; clozapine; monkey; Nr4a1; transcription factor

Indexed keywords

MESSENGER RNA; NUCLEAR RECEPTOR NUR77;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CEBUS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; IN SITU HYBRIDIZATION; MOLECULAR PATHOLOGY; NONHUMAN; NUCLEAR RECEPTOR NUR77 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; TARDIVE DYSKINESIA;

ABNORMAL INVOLUNTARY MOVEMENTS; ANTIPSYCHOTIC DRUG; CLOZAPINE; MONKEY; NR4A1; TRANSCRIPTION FACTOR;

ANIMALS; ANTIPSYCHOTIC AGENTS; CEBUS; CLOZAPINE; CORPUS STRIATUM; FEMALE; HALOPERIDOL; MOVEMENT DISORDERS; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; PUTAMEN; RNA, MESSENGER; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84879837625     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/ejn.12198     Document Type: Article

References (41)

1. Beaudry, G., Langlois, M.-C., Weppe, I., Rouillard, C. & Lévesque, D. (2000) Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor Nerve Growth Factor-Inducible B by haloperidol and clozapine in the rat forebrain. J. Neurochem., 75, 1694-1702.
2. Berger, B., Gaspar, P. & Verney, C. (1991) Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates [published erratum appears in Trends Neurosci 1991 Mar; 14(3):119]. Trends Neurosci., 14, 21-27.
3. Blanchet, P.J., Parent, M.T., Rompré, P.H. & Lévesque, D. (2012) Relevance of animal models to human tardive dyskinesia. Behav. Brain Funct., 8, 12.
4. 2 dopamine receptor antagonists on Fos protein expression in the striatal complex and entorhinal cortex of the nonhuman primate. Synapse, 23, 182-191.
5. Ethier, I., Beaudry, G., St-Hilaire, M., Milbrandt, J., Rouillard, C. & Lévesque, D. (2004a) The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic-induced extrapyramidal effect and striatal neuropeptide gene expression. Neuropsychopharmacol., 29, 335-346.
6. Ethier, I., Kagechika, H., Shudo, K., Rouillard, C. & Lévesque, D. (2004b) Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: involvement of Nur77 and retinoid receptors. Biol. Psychiat., 56, 522-526.
7. Grande, C., Zhu, H.W., Martin, A.B., Lee, M., Ortiz, O., Hiroi, N. & Moratalla, R. (2004) Chronic treatment with atypical neuroleptics induces striosomal FosB/ΔFosB expression in rats. Biol. Psychiat., 55, 457-463.
8. Gunne, L.M. & Barany, S. (1979) A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesia. Psychopharmacology, 63, 195-198.
9. van Harten, P.N. & Tenback, D.E. (2011) Tardive dyskinesia: clinical presentation and treatment. Int. Rev. Neurobiol., 98, 187-210.
10. Herdegen, T. & Leah, J.D. (1998) Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res. Brain Res. Rev., 28, 370-490.
11. Herrera, D.G. & Robertson, H.A. (1996) Activation of c-fos in the brain. Prog. Neurobiol., 50, 83-107.
12. Joel, D. & Weiner, I. (2000) The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience, 96, 451-474.
13. Jones, P.B., Barnes, T.R., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K.P., Murray, R.M., Markwick, A. & Lewis, S.W. (2006) Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiat., 63, 1079-1087.
14. Kenney, C., Hunter, C., Davidson, A. & Jankovic, J. (2008) Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J. Clin. Pharmacol., 48, 379-384.
15. Kumar, R., Palit, G. & Dhawan, B.N. (2003) Comparative behavioural effects of typical and atypical antipsychotic drugs in rhesus monkey. Eur. J. Pharmacol., 462, 133-138.
16. Langlois, M.-C., Beaudry, G., Zekki, H., Rouillard, C. & Lévesque, D. (2001) Impact of antipsychotic drug administration on the expression of nuclear receptors in the neocortex and striatum of the rat brain. Neuroscience, 106, 117-128.
17. Lee, P.E., Sykora, K., Gill, S.S., Mamdani, M., Marras, C., Anderson, G., Shulman, K.I., Stukel, T., Normand, S.L. & Rochon, P.A. (2005) Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J. Am. Geriatr. Soc., 53, 1374-1379.
18. de Leon, J. (2007) The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. Eur. Arch. Psy. Clin. N., 257, 169-172.
19. Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C. & Davis, J.M. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 373, 31-41.
20. Lévesque, D. & Rouillard, C. (2007) Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation. Trends Neurosci., 30, 22-30.
21. 2-dopaminergic receptors in the primate cerebral cortex. Proc. Natl. Acad. Sci. USA, 91, 4353-4356.
22. Maheux, J., Ethier, I., Rouillard, C. & Lévesque, D. (2005) Induction patterns of transcription factors of the Nur family (Nurr1, Nur77 and Nor-1) by typical and atypical antipsychotics in the mouse brain: implication for their mechanism of action. J. Pharmacol. Exp. Ther., 313, 460-473.
23. Maheux, J., Vuillier, L., Mahfouz, M., Rouillard, C. & Lévesque, D. (2012) Modulation of haloperidol-induced patterns of the transcription factor Nur77 and Nor-1 expression by serotonergic and adrenergic drugs in the mouse brain. Int. J. Neuropsychop., 15, 509-521.
24. Mahmoudi, S., Samadi, P., Gilbert, F., Ouattara, B., Morissette, M., Grégoire, L., Rouillard, C., Di Paolo, T. & Lévesque, D. (2009) Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid. Neurobiol. Dis., 36, 213-222.
25. Miyamoto, S., Duncan, G.E., Marx, C.E. & Lieberman, J.A. (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatr., 10, 79-104.
26. Nambu, A. (2011) Somatotopic organization of the primate Basal Ganglia. Front. Neuroanat., 5, 26.
27. Novak, G., Gallo, A., Zai, C.C., Meltzer, H.Y., Lieberman, J.A., Potkin, S.G., Voineskos, A.N., Remington, G., Kennedy, J.L., Lévesque, D. & Le Foll, B. (2010) Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. Psychiatr. Genet., 20, 39-43.
28. Parent, A. & Hazrati, L.-N. (1995) Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Brain Res. Rev., 20, 91-127.
29. Pasricha, P.J., Pehlivanov, N., Sugumar, A. & Jankovic, J. (2006) Drug Insight: from disturbed motility to disordered movement - a review of the clinical benefits and medicolegal risks of metoclopramide. Nat. Clin. Pract. Gastr., 3, 138-148.
30. Paxinos, G. (2009) The Rherus Monkey Brain in Stereotaxic Coordinates. Academic Press, Boston.
31. Peacock, L. & Gerlach, J. (1999) New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects. Psychopharmacology, 144, 189-197.
32. Peluso, M.J., Lewis, S.W., Barnes, T.R. & Jones, P.B. (2012) Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Brit. J. Psychiat., 200, 387-392.
33. Perlmann, T. & Jansson, L. (1995) A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1. Gene. Dev., 9, 769-782.
34. Rodriguez, J.J., Garcia, D.R., Nakabeppu, Y. & Pickel, V.M. (2001) FosB in rat striatum: normal regional distribution and enhanced expression after 6-month haloperidol administration. Synapse, 39, 122-132.
35. Rosenheck, R., Perlick, D., Bingham, S., Liu-Mares, W., Collins, J., Warren, S., Leslie, D., Allan, E., Campbell, E.C., Caroff, S., Corwin, J., Davis, L., Douyon, R., Dunn, L., Evans, D., Frecska, E., Grabowski, J., Graeber, D., Herz, L., Kwon, K., Lawson, W., Mena, F., Sheikh, J., Smelson, D. & Smith-Gamble, V. (2003) Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA, 290, 2693-2702.
36. Shim, J. & Karin, M. (2002) The control of mRNA stability in response to extracellular stimuli. Mol. Cells, 14, 323-331.
37. Tarsy, D. & Baldessarini, R.J. (2006) Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Movement Disord., 21, 589-598.
38. 2 receptor occupancy? Neurosci. Biobehav. R., 26, 361-380.
39. Werme, M., Ringholm, A., Olson, L. & Brené, S. (2000) Differential patterns of induction of NGFI-B, Nor1 and c-fos mRNAs in striatal subregions by haloperidol and clozapine. Brain Res., 863, 112-119.
40. Woods, S.W., Morgenstern, H., Saksa, J.R., Walsh, B.C., Sullivan, M.C., Money, R., Hawkins, K.A., Gueorguieva, R.V. & Glazer, W.M. (2010) Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J. Clin. Psychiat., 71, 463-474.
41. Yassa, R. & Jeste, D.V. (1992) Gender differences in tardive dyskinesia: a critical review of the literature. Schizophrenia Bull., 18, 701-715.